This comprehensive volume covers radiopharmaceuticals developed for pathway-directed systems in
imaging and theranostic applications. We now are at the cutting edge of providing personalized
treatment with increased use in oncology of these new radiopharmaceuticals. Trends in
high-resolution instrumentation development quality assurance systems and regulatory
compliance for radiopharmaceuticals clinical evaluation of radiopharmaceuticals and benefits
and pitfalls of the current clinical FDG PET are discussed.Radiopharmaceuticals are used for
diagnosis of diseases of the central nervous and cardiovascular systems and for staging
restaging and treatment planning for cancers. Nuclear biomarkers allow precise measurement of
molecular pathways on a whole-body image upon administration of functional radiolabeled agents
and nuclear imaging agents have potential use in patient selection pharmacokinetic
dosage-finding and proof-of-concept studies. Nuclear imaging agents and hybrid instrumentation
also provide sensitive and specific answers for differential responsiveness in therapeutic
outcome.This book serves as a reference for moving the discovery and development of
radiopharmaceuticals from the workbench to clinical applications. It thus benefits not only
clinicians but also translational research scientists-molecular biologists chemists imaging
scientists pharmaceutical developers physicists and support staff.
